Search

Displaying results 5681 - 5690 of 10000 in total
  1. Drug

    Eptazocine

    go.drugbank.com/drugs/DB19670
    Experimental

    The usage of the INN stem '-azocine' in the name indicates that Eptazocine is a narcotic antagonist/agonist related to 6,7-benzomorphan. Eptazocine has a monoisotopic molecular weight of 231.16 Da.

  2. Drug

    Ganulameran

    go.drugbank.com/drugs/DB16442
    Investigational

    The BNT162b3 vaccine is the latest addition to BioNTech and partner Pfizer’s mRNA COVID-19 vaccine program. Similar to [BNT162b2], BNT162b3 uses a nucleoside-modified RNA (modRNA) technology. … Pfizer and BioNTech deemed this compound as promising in preclinical trials and have decided to initiate further testing of it.

  3. Drug

    Piclamilast

    go.drugbank.com/drugs/DB01791
    Experimental

    It has been investigated for its applications to the treatment of conditions such as chronic obstructive pulmonary disease, bronchopulmonary dysplasia and asthma. … The structure for piclamilast was first elucidated in a 1995 European patent application and exhibits the structural functionalities of cilomilast and roflumilast.

  4. Drug

    Decoquinate

    go.drugbank.com/drugs/DB11394
    ExperimentalVet approved

    Decoquinate is used in veterinary to delay the growth and reproduction of coccidian parasites.

  5. Drug

    Recombinant Cholera Toxin B Subunit

    go.drugbank.com/drugs/DB11643
    ApprovedInvestigational

    Recombinant Cholera Toxin B Subunit is an ingredient in the EMA-authorised product Dukoral.

  6. Drug

    Ferrimannitol ovalbumin

    go.drugbank.com/drugs/DB15824
    Investigational

    Ferrimannitol-ovalbumin (FMOA) is an adduct between ovalbumin and the complex Fe(III)-mannitol.

  7. Drug

    Yttrium Y-90

    go.drugbank.com/drugs/DB13076
    ApprovedInvestigational

    Yttrium 90 has been investigated for the treatment of Colon Cancer and Colorectal Cancer.

  8. Drug

    Alferminogene tadenovec

    go.drugbank.com/drugs/DB05306
    Investigational

    Alferminogene tadenovec, Cardium’s lead product candidate, is being developed for the potential treatment of myocardial ischemia that gives rise to angina symptoms associated with coronary heart disease … Alferminogene tadenovec represents a new therapeutic class of biologics designed to promote angiogenesis and thereby improve blood flow following a one-time intracoronary administration from a standard

  9. Drug

    Inhibitor of P38 Kinase

    go.drugbank.com/drugs/DB01953
    Experimental

    This compound belongs to the indoles. These are compounds containing an indole moiety, which consists of a pyrrole ring fused to benzene to form 2,3-benzopyrrole. … This drug is known to target mitogen-activated protein kinase 14.

  10. Drug

    Bevirimat

    go.drugbank.com/drugs/DB06581
    Investigational

    This compound belongs to the androgens and derivatives, which are hydroxylated C19 steroid hormones. They are known to favour the development of masculine characteristics. … It is not currently FDA-approved, but is undergoing clinical trials conducted by the pharmaceutical company Panacos.